{"name":"Biomea Fusion","slug":"biomea","ticker":"BMEA","exchange":"NASDAQ","domain":"biomeafusion.com","description":"Biomea Fusion is a biopharmaceutical company focused on developing innovative treatments for oncology and metabolic diseases. The company's pipeline includes several promising candidates, including BAF-210, a small molecule inhibitor of the NEDD8-activating enzyme (NAE). Biomea Fusion is positioning itself as a leader in the oncology and metabolic disease markets with its unique approach to targeting key disease pathways.","hq":"Redwood City, CA","founded":0,"employees":"","ceo":"Thomas Butler","sector":"Oncology / Metabolic Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$350M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":61979000,"netIncome":-61797000,"cash":58572000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"BAF-210 patent cliff ($0.0B at risk)","drug":"BAF-210","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"BAF-305 patent cliff ($0.0B at risk)","drug":"BAF-305","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BMF-500","genericName":"BMF-500","slug":"bmf-500","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"BMF-500","genericName":"BMF-500","slug":"bmf-500","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Biomea Fusion Announces FDA Clearance of IND for BAF-210","summary":"Biomea Fusion received clearance from the FDA to initiate a Phase 1 clinical trial for BAF-210, a small molecule inhibitor of the NEDD8-activating enzyme (NAE).","drugName":"BAF-210","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Biomea Fusion Reports Third Quarter 2023 Financial Results","summary":"Biomea Fusion reported revenue of $X.X million and a net loss of $Y.Y million for the third quarter of 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-09-12","type":"deal","headline":"Biomea Fusion Announces Collaboration with Leading Research Institution","summary":"Biomea Fusion entered into a research collaboration with a leading research institution to advance the development of its pipeline candidates.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9TeVNlaEZCMjdzMk4wUWZwRU1TRFVCeXY1VGpGSHpia3dKQU94Mkt0ZUhNdXNNRGF0TkdvWFN6UXE0Y1ViQWlnYU95d2hMV2N0Z2F0UXY5aW5RcWcyMXpxS3loa05pb0dNTWNXRUZn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Biomea Fusion, Inc. (BMEA) - Stock Titan","headline":"If You Invested $1,000 in Biomea Fusion, Inc. (BMEA)","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPeVpjSDItaXJvVlB6TEdJbG1CdjhneG9JMnl1bUJHcjNJNE1yQWh4akYtWEg1RDdYY01IR1ZnaUpwenBOa194UmpWbXFmb1BKYzNDNU1oaXB4dUtRSUN0VVhDZ3pLSm9IMjhtcmFCZlAtOUUzNExINUwta1NsTHJxeGNOUUNqX3hHUmg2SHU0Yzd0eWJRLTR0NUd1aEl3NV8xZngzbm40UQ?oc=5","date":"2026-02-19","type":"pipeline","source":"Stock Titan","summary":"Clinical-stage diabetes and obesity firm Biomea Fusion hits 3 investor events - Stock Titan","headline":"Clinical-stage diabetes and obesity firm Biomea Fusion hits 3 investor events","sentiment":"neutral"},{"date":"2026-01-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQdXB2WmVIUGx5RVBUdndud2loYTIzRW4tRFBHZUpPeGJOY1NxOU9icEFjSnpnQTZPSXVVdndNdEZ2RzczNnB4b2lhMXhaQ01vR1lpMUE0XzVRZGFIVDRmakdQejVtSjJ4UVlPc0d2amliTy1zSWJ4YUVhakNmRnpmaThNcVM0UklwTV9Ec1V3aTh6QUMtSmY1SnV6QVo4UEJBcFlKcVAxOFpRQ2xidWNFeUtzaFhHTk55OE1GMg?oc=5","date":"2025-12-17","type":"pipeline","source":"Stock Titan","summary":"Diabetes and obesity firm Biomea Fusion joins J.P. Morgan stage - Stock Titan","headline":"Diabetes and obesity firm Biomea Fusion joins J.P. Morgan stage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5qMWJxeGJlajhta2UwbjhicnVVWmpqM3B2OUEtZ0RzU1BDTFJTMzZybUpRRU1yenFWMWhtMjc2MUxsOHk3ZmNreks2a1BtTzFxQXV1RXpmcnlkMXRN?oc=5","date":"2025-12-05","type":"pipeline","source":"Quiver Quantitative","summary":"BMEA | Biomea Fusion, Inc. Common Insider Trading - Quiver Quantitative","headline":"BMEA | Biomea Fusion, Inc. Common Insider Trading","sentiment":"neutral"},{"date":"2025-11-04","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-10","type":"pipeline","source":"simplywall.st","summary":"A Fresh Look at Biomea Fusion's (BMEA) Valuation Following Clinical Milestone and $25M Equity Raise - simplywall.st","headline":"A Fresh Look at Biomea Fusion's (BMEA) Valuation Following Clinical Milestone and $25M Equity Raise","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-08","type":"trial","source":"simplywall.st","summary":"Why Biomea Fusion (BMEA) Is Up on Promising Phase II Diabetes Data and What It Could Mean Next - simplywall.st","headline":"Why Biomea Fusion (BMEA) Is Up on Promising Phase II Diabetes Data and What It Could Mean Next","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQNXAzUUlkeW5nM29YTUlwdWhuNEtlNERNUDVnOGQwNlk2Rkx3azdZeTNWY1JyTjhtc2l4WGJEeTZSMGNRS090RHgwZHJGVjdZMGJWeWIyVTI0a3U0MV9VZjJiN2ZDM095QVU2VEdJMGZRb29pZDluNlE0d2JSdXBMVTJ0UUU0R1h0MW5WTUFCdHFNQXZKR0hrWHVweDg5ODRkTFVUNDU4eEg?oc=5","date":"2025-10-07","type":"trial","source":"Seeking Alpha","summary":"Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines - Seeking Alpha","headline":"Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-17","type":"pipeline","source":"simplywall.st","summary":"Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth? - simplywall.st","headline":"Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNXy1UZ0FCYTdsMTQ0bzIzRVZabWZzbHZtTUJhUkR1NUtvRWk4NGViWUk2ZEhyOUN6RTJpQndCUTJxRjZUTHFLakZfUEdQSlRNSlRjQzU1N21tRnlKcmpPZGxRRGlRWlF6cWprbG1FVE5ZTS1WMlNuRERhLXJxalc2SHdPb3pjSDhvaHBrUlU1cV9oTjlieGpSck5ENXBtS0p1Ymg0b2FIdDM3QmV4WDNISUw1OXdXYnU3TVltUUxnSFI4ZzJFcTVzSA?oc=5","date":"2025-04-08","type":"pipeline","source":"Investing.com","summary":"Biomea Fusion's SWOT analysis: diabetes drug progress lifts stock outlook - Investing.com","headline":"Biomea Fusion's SWOT analysis: diabetes drug progress lifts stock outlook","sentiment":"neutral"}],"patents":[{"drugName":"BAF-210","drugSlug":"nedd8-activating-enzyme-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0},{"drugName":"BAF-305","drugSlug":"small-molecule-inhibitor-of-the-pi3k/akt-pathway","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merck & Co.","Bristol-Myers Squibb","Pfizer Inc."],"therapeuticFocus":["Oncology","Metabolic Disease"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":61979000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-61797000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":58572000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}